Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive crawled date : 2021 - 12 - 14 save search
Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-14 (Crawled : 20:00) - biospace.com/
LTRN | News | $5.44 -5.72% -6.07% 96K
|
Health Technology
|
| O: 0.13%
H: 1.57%
C: -1.77%
lp-284 ema positive cancer
Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Published: 2021-12-14 (Crawled : 15:30) - biospace.com/
CDTX | News | $11.94 16.49% 14.15% 170K
|
Health Technology
|
| O: -15.03%
H: 0.36%
C: -14.8%
treatment trial therapeutics topline results positive results topline phase 3 candidemia
Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-14 (Crawled : 14:30) - biospace.com/
EMMA | $0.0921 385.44% 66K
|
Professional, Scientific, and T...
|
| O: -0.33%
H: 2.65%
C: -2.65%
endari ema transfusion disease cel positive life science phase 3
Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines; Development Program for SBP-101’s Expansion into Ovarian Cancer Expected in 1H 2022
Published: 2021-12-14 (Crawled : 14:00) - globenewswire.com
PBLA | News | $0.42 -6.31% 64K
|
Professional, Scientific, and T...
|
| O: 2.91%
H: 1.69%
C: -6.78%
sbp-101 expansion ovarian cancer cel preclinical positive cancer pre-clinical
Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
Published: 2021-12-14 (Crawled : 12:30) - biospace.com/
IMUX | $1.24 0.0% 130K
|
Health Technology
|
| O: -3.49%
H: 1.75%
C: -6.36%
imu-935 trial positive results phase 1 potential positive results
HEXO Reports First Quarter 2022 Results and Launches New Strategic Plan, “The Path Forward” to Solidify its Position as Canada’s Leading Cannabis Company
Published: 2021-12-14 (Crawled : 12:30) - globenewswire.com
HEXO | $0.71 -0.14% 310K
|
Process Industries
|
| O: -7.78%
H: 4.32%
C: -3.27%
cannabis results positive
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-14 (Crawled : 06:00) - biospace.com/
ATRA | $0.7101 -1.18% -1.2% 700K
|
Health Technology
|
| O: -4.53%
H: 4.22%
C: 2.01%
cel ema trial therapeutics positive results tab-cel positive results phase 3 iot
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.